Advertisement

Topics

J&J Brushes Off Looming Biosimilar Competition

11:23 EDT 18 Oct 2016 | Wall Street Journal

Johnson & Johnson sought to reassure investors and analysts that lower-priced competition for one of its top-selling products won’t slow a company that posted slightly better-than-expected results in the third quarter.

Original Article: J&J Brushes Off Looming Biosimilar Competition

NEXT ARTICLE

More From BioPortfolio on "J&J Brushes Off Looming Biosimilar Competition"

Quick Search
Advertisement
 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...